BRCA2 and non-small cell lung carcinoma: HRD prevalence in colorectal (10–15%), pancreatic (15–20%), NSCLC (5–10%), and prostate (20–25%) cancers suggests therapeutic potential, with trials like TRITON2 showing olaparib PFS of 8.1 months in BRCA2-mutated prostate cancer.